Program
Megestrol Acetate
Also written as “Nano-crystalline Megestrol Acetate Oral Suspension”, “Megestrol acetate concentrated suspension 125 mg/mL” and “Megestrol acetate”.
Its studies are mostly in Anorexia · Cachexia · Neoplasms · Carcinoma, Non-Small-Cell Lung · Neoplasm Metastasis, led by 6 companies.
Drug pageMegestrol Acetate: every studyMany companies study it; this page follows only the 18 they lead. All 66 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Changchun GeneScience Pharmaceuticalits history only | 77 open or running | phase 4since Nov 15, 2025 | Dec 25, 2024 | Dec 31, 2026phase 4 · NCT07243379 |
| Bristol-Myers Squibbits history only | 30 open or running | phase 4since Nov 2, 1999 | Nov 2, 1999 | none ahead |
| Par Healthits history only | 30 open or running | phase 3since Mar 11, 2008 | Mar 11, 2008 | none ahead |
| Keenova Therapeuticsits history only | 20 open or running | phase 2since Mar 11, 2008 | Mar 11, 2008 | none ahead |
| Rottapharm Spainits history only | 20 open or running | phase 3since Jul 17, 2007 | Jul 17, 2007 | none ahead |
| TTY Biopharm | 10 open or running | phase 2since Jul 25, 2016 | Jul 25, 2016 | none ahead |
Also a collaborator on its studies: Quintiles, Covance, SFBC Anapharm and PRA Health Sciences.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of TTY Biopharm only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jul 25, 2016First study: phase 2 study in Head and Neck NeoplasmsFirst studyNCT02980653 · 105 enrolled · Taiwan
TargetBeta
“Progesterone receptor agonist”ChEMBL 37, by rule
Other programs on PGR
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Levonorgestrelrule | Bayer | phase 4 | 56 |
| drospirenonerule | estetra | phase 4 | 20 |
| Medroxyprogesterone Acetaterule | Pfizer | phase 4 | 11 |
| Cyproterone Acetaterule | Eurofarma Laboratorios | phase 3 | 4 |
| Utrogestanrule | calla-lily-clinical-care-ltd | phase 1 | 1 |
Studies
The one study TTY Biopharm leads. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT02980653Head and Neck Neoplasms · Taiwan | 2 | UNKNOWN | Aug 2017 | 105 |
How it is read
Names in the registry
- “Nano-crystalline Megestrol Acetate Oral Suspension”, 5 entries
- “Megestrol acetate concentrated suspension 125 mg/mL”, 5 entries
- “Megestrol acetate”, 5 entries
- “Nanocrystalline Megestrol Acetate”, 2 entries
- “Megestrol acetate concentrated suspension 110 mg/mL”, 2 entries
Conditions, from the studies’ own filings
- Anorexia, 5 studies
- Cachexia, 2 studies
- Neoplasms, 1 study
- Carcinoma, Non-Small-Cell Lung, 1 study
- Neoplasm Metastasis, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.